Utolsó frissítés :
19/11/2024
Helyi érzéstelenítő   Bupivacaine hydrochloride  
Injekció
Az oldatok stabilitása A keverékek stabilitása Stabilitást befolyásoló tényezők Kompatibilitás Az alkalmazás módja Irodalom pdf
   Kémiai szerkezet   

Kereskedelmi név   Kereskedelmi név     

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Bicain Finnország
Bucain Ausztria, Németország
Bucaine Szaúd-Arábiában
Bupi Alleman Németország
Bupinest Colombia, Ecuador
Bupirop Ecuador
Bupisen Olaszország
Bupivacain Németország
Bupivacaina Chile, Spanyolország
Bupivacaine Ausztrália, Írország, Marokkó, Nagy-Britannia, Tunézia
Bupivan Chile, Németország
Buvacaina Mexikó
Buvasin Törökország
Carbostesin Ausztria, Németország
Dolanaest Ausztria, Németország
Duracaine Argentína
Inibsacain Spanyolország
Marcain Ausztrália, Dánia, Egyiptom, Malaysia, új-Zéland
Marcaine Belgium
Sensorcaine Kanada
Sinebupiv Ecuador
Irodalom   Injekció   Irodalom : Bupivacaine hydrochloride  
Type publikáció
60 Napló Tu YH, Stiles ML, Allen LV Jr.
Stability of fentanyl citrate and bupivacaine hydrochloride in portable pump reservoirs.
Am J Hosp Pharm 1990 ; 47: 2037-2040.
217 Napló Allen LV, Stiles ML, Wang DP, Tu YH.
Stability of bupivacaine hydrochloride, epinephrine hydrochloride, and fentanyl citrate in portable infusion-pump reservoirs.
Am J Hosp Pharm 1993 ; 50: 714-715.
220 Napló Johnson CE, Christen C, Perez MM, Ma M.
Compatibility of bupivacaine hydrochloride and morphine sulfate.
Am J Health-Syst Pharm 1997 ; 54: 61-64.
221 Napló Neels JT.
Compatibility of bupivacaine hydrochloride with hydromorphone hydrochloride or morphine sulfate.
Am J Hosp Pharm 1992 ; 49: 2149.
293 Napló Jones JW, Davis AT.
Stability of bupivacaine hydrochloride in polypropylene syringes.
Am J Hosp Pharm 1993 ; 50: 2364-2365.
306 Napló Christen C, Johnson CE, Walters JR.
Stability of bupivacaine hydrochloride and hydromorphone hydrochloride during simulated epidural coadministration.
Am J Health-Syst Pharm 1996 ; 53: 170-173.
346 Napló Wulf H, Gleim M, Mignat C.
The stability of mixtures of morphine hydrochloride, bupivacaine hydrochloride, and clonidine hydrochloride in portable pump reservoirs for the management of chronic pain syndromes.
J Pain Symptom Manage 1994 ; 9: 308-311.
507 Napló Dawson PJ, Bjorksten AR, Duncan IP, Barnes RK, Beemer GH.
Stability of fentanyl, bupivacaine and adrenaline solutions for extradural infusion.
Br J Anaesth 1992 ; 68: 414-417.
510 Napló Roos PJ, Glerum JH, Schroeders MJH.
Effect of glucose 5% solution and bupivacaine hydrochloride on absorption of sufentanil citrate in a portable pump reservoir during storage and simulated infusion by an epidural catheter.
Pharm World Sci 1993 ; 15: 269-275.
512 Napló Barnes AR, Nash S.
Stability of bupivacaine hydrochloride with diamorphine hydrochloride in an epidural infusion.
Pharm World Sci 1995 ; 17: 87-92.
529 Napló Van Asten P, Glerum JH, Spaanderman ER, Van Niekerk J, Van Dijk A.
Compatibility of bupivacaine and iohexol in two mixtures for paediatric regional anaesthesia.
Pharm Weekbl [Sci] 1991 ; 13: 254-256.
1276 Napló Shiffman E, Walker SE, Yoon T, Yeung M.
Stability and compatibility of morphine with bupivacaine.
Can J Hosp Pharm 1998 ; 51: 110-116.
1292 Napló Grassby PF, Roberts DE.
Stability of epidural opiate solutions in 0.9 per cent sodium chloride infusion bags.
Int J Pharm Pract 1995 ; 3: 174-177.
1491 Napló Brouwers JRBJ, van Doorne H, Meevis RF, Boersma FP.
Stability of sufentanil citrate and sufentanil citrate/bupivacaine mixture in portable infusion pump reservoirs.
Eur Hosp Pharm 1995 ; 1: 12-14.
1707 Napló Trissel LA, Xu QA, Pham L.
Physical and chemical stability of low and high concentrations of morphine sulfate with bupivacaine hydrochloride packaged in plastic syringes.
Int J Pharm Compound 2002 ; 6: 70-73.
1723 Napló Sattler A, Jage J, Krämer I.
Physico-chemical stability of infusion solutions for epidural administration containing fentanyl and bupivacaine or lidocaine.
Pharmazie 1998 ; 53: 386-391.
1875 Napló Kjonniksen I, Brustugun J, Breivik H, Anderssen E, Klem W.
Stability of an epidural analgesic solution containing adrenaline, bupivacaine and fentanyl.
Acta Anaesthesiol Scand 2000 ; 44: 864-867.
1879 Napló Hildebrand KR, Elsberry DE, Deer TR.
Stability, compatibility, and safety of intrathecal bupivacaine administered via an implantable delivery system.
Clin J Pain 2001 : 17: 239-244.
1885 Napló Essink-Tjebbes CM, Burger DM, Beelen, Wuis EW, Heckster YA.
Long-term stability of morphine and bupivacaine mixture for spinal use.
Pharm World Sci 1999 ; 21: 144-146.
1909 Napló Farhang-Asnefi S, Barre J, Callaert S, Boutros A, Causse R, Thebault A.
Compatibilité et stabilité du mélange bupivacaïne-sufentanil en poche.
J Pharm Clin 2000 ; 19: 248-251.
1931 Napló Donnely RF.
Physical compatibility and chemical stability of bupivacaine and hydromorphone in polypropylene syringes.
Can J Hosp Pharm 2004 ; 4: 230-235.
1948 Napló Classen AM, Wimbish GH, Kupiec TC.
Stability of admixtures containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system.
J Pain Symptom Manage 2004 ; 28, 6: 603-611.
2083 Napló La Forgia SP, Sharley NA, Burgess NG, Doecke CJ.
Stability and compatibility of morphine, midazolam and bupivacaine combinaisons for iontravenous infusion.
J Pharm Pract and Res 2002 ; 32: 65-68.
2252 Napló Shields D, Montenegro R, Aclan J.
Chemical stability of admixture combining ziconotide and bupivacaine during simulated intrathecal administration.
Neuromodulation 2007 ; 10, 1: 1-5.
2305 Napló Bianchi F, Ginggen A, Tardy Y.
Stability and compatibility of drug mixtures in an implantable infusion system.
Anaesthesia 2008 63, 9: 972-978.
2306 Napló Priston M.J, Hughes J.M, Santillo M, Christie I.W.
Stability of an epidural analgesic admixture containing epinephrine, fentanyl and bupivacaine.
Anaesthesia 2004 ; 59, 10: 979-983.
2307 Napló Kreeger L, Cowin P, Noble-Gresty J, Naysmith A.
Epidural diamorphine and bupivacaine stability study.
Palliative Med 1995 ; 9, 4: 315-318.
2308 Napló Hudson S.J, Jones M.F, Nolan S, Ellis H, Duncombe R, Alexander-Williams J.M.
Stability of premixed syringes of diamorphine and hyperbaric bupivacaine.
Int J Obstet Anesth 2005 ; 14, 4: 284-287.
2319 Napló Janssen K, Wisselo R, Geerlings C, Schouten J.P.
Chemical stability of a solution of bupivacaine hydrochloride 0.125% and sufentanil citrate 0.5 µg/ml for filling syringes using a repeater pump.
EJHP Science 2009 ; 15, 1: 11-14.
3131 Napló Donnely RF, Wong K, Spencer J.
Physical compatibility of high-concentration bupivacaine with hydromorphone, morphine and fentanyl.
Can J Hosp Pharm 2010 ; 63, 2: 154-155.
3184 Laboratórium
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005
3296 Napló Salmeron-Garcia A, Navas N, Martin A, Roman E, Cabeza J, Capitan-Vallvey L.F
Determination of Tramadol, Metamizole, Ropivacaine, and Bupivacaine in Analgesic Mixture Samples by HPLC with DAD Detection.
J Chromatographic Sci 2009 ; 47: 1-7.
3372 Napló Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3964 Napló Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4200 Napló Macorigh C, Guibbert V, Casanova M, Haenni C.
Stability study of hydromorphone and bupivacaine mixture by HPLC-UV.
EJHP 2018
4319 Napló Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4603 Napló Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4746 poszter Shead K, Derrick H, Lyons D, Law S, Ma N.H.
Stability and Compatibility of Bupivacaine and Hydromorphone in PVC and non-DEHP bags for 30 days at 4°C and 25°C.
2023

  Mentions Légales